PLASMA KALLIKREIN AND PRORENIN IN PATIENTS WITH HEREDITARY ANGIOEDEMA

被引：0
|
作者：
PURDON, AD
SCHAPIRA, M
DEAGOSTINI, A
COLMAN, RW
机构：
[1] TEMPLE UNIV,HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR,3400 N BROAD ST,PHILADELPHIA,PA 19140
[2] TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MED,CTR THROMBOSIS RES,HEMATOL & ONCOL SECT,PHILADELPHIA,PA 19140
[3] HOP CANTONAL UNIV,DEPT RHEMAT,GENEVA,SWITZERLAND
来源：
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 1985年 / 105卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：694 / 699
页数：6
相关论文
共 50 条
  • [1] Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
    Banerji, A.
    Busse, P.
    Shennak, M.
    Lumry, W.
    Davis-Lorton, M.
    Wedner, H. J.
    Jacobs, J.
    Baker, J.
    Bernstein, J. A.
    Lockey, R.
    Li, H. H.
    Craig, T.
    Cicardi, M.
    Riedl, M.
    Al-Ghazawi, A.
    Soo, C.
    Iarrobino, R.
    Sexton, D. J.
    TenHoor, C.
    Kenniston, J. A.
    Faucette, R.
    Still, J. G.
    Kushner, H.
    Mensah, R.
    Stevens, C.
    Biedenkapp, J. C.
    Chyung, Y.
    Adelman, B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08): : 717 - 728
  • [2] Ecallantide - Plasma kallikrein inhibitor, treatment of hereditary angioedema
    Revill, P.
    Mealy, N.
    [J]. DRUGS OF THE FUTURE, 2007, 32 (07) : 590 - 594
  • [3] Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
    Aygoeren-Puersuen, E.
    Bygum, A.
    Grivcheva-Panovska, V.
    Magerl, M.
    Graff, J.
    Steiner, U. C.
    Fain, O.
    Huissoon, A.
    Kinaciyan, T.
    Farkas, H.
    Lleonart, R.
    Longhurst, H. J.
    Rae, W.
    Triggiani, M.
    Aberer, W.
    Cancian, M.
    Zanichelli, A.
    Smith, W. B.
    Baeza, M. L.
    Du-Thanh, A.
    Gompels, M.
    Gonzalez-Quevedo, T.
    Greve, J.
    Guilarte, M.
    Katelaris, C.
    Dobo, S.
    Cornpropst, M.
    Clemons, D.
    Fang, L.
    Collis, P.
    Sheridan, W.
    Maurer, M.
    Cicardi, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04): : 352 - 362
  • [4] Pharmacodynamic Effect of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
    Davis-Lorton, Mark A.
    Busse, Paula J.
    Banerji, Aleena
    Shennak, Mustafa
    Lumry, William R.
    Wedner, H. James
    Jacobs, Joshua S.
    Baker, James W.
    Bernstein, Jonathan A.
    Lockey, Richard F.
    Li, H. Henry
    Craig, Timothy J.
    Marco-Cicardi
    Riedl, Marc A.
    Al-Ghazawi, Ahmad
    Soo, Carolyn
    Iarrobino, Ryan
    Sexton, Daniel
    TenHoor, Christopher
    Faucette, Ryan
    Biedenkapp, Joseph C.
    Chyung, Yung H.
    Adelman, Burt
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB252 - AB252
  • [5] Kallikrein Inhibition for Hereditary Angioedema
    Longhurst, Hilary J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (08): : 788 - 789
  • [6] ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
    Stolz, L. E.
    Horn, P. T.
    [J]. DRUGS OF TODAY, 2010, 46 (08) : 547 - 555
  • [7] RELEVANCE OF PLASMA KALLIKREIN (PKAL) LEVELS FOR LANADELUMAB PHARMACOKINETICS (PK) IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE).
    Ahmed, M.
    Wang, Y.
    Zhu, A.
    Sexton, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S5 - S6
  • [8] Treatment-specific normalization of plasma kallikrein activity observed in patients with Hereditary Angioedema (HAE)
    Inhaber, N.
    Zhou, Z.
    Lu, P.
    Bernstein, J. A.
    Sexton, D.
    Chockalingam, P. S.
    [J]. ALLERGY, 2020, 75 : 197 - 197
  • [9] Plasma kallikrein activation in patients with hereditary angioedema due to C1 inhibitor deficiency
    Zanichelli, A.
    Maggioni, L.
    Cicardi, M.
    [J]. ALLERGY, 2009, 64 : 571 - 572
  • [10] Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade
    Busse, Paula
    Kaplan, Allen
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (03): : 716 - 722
12345